The Global Primary Biliary Cholangitis Treatment Market, by Treatment Type (Obeticholic acid (Ocaliva) and Ursodeoxycholic acid (UDCA)), by Distribution Channels (Hospital Pharmacies, Online Pharmacies and Retail Pharmacies). In 2017, the market was worth US$ 526.4 million, and it is expected to grow at a CAGR of 36.3 percent over the forecast period (2018 – 2026).
The primary biliary cholangitis treatment market is predicted to grow due to an increase in pipeline research to create prominent medicines for rare diseases such as primary biliary cholangitis. For example, Zydus Discovery DMCC started a phase 2 clinical trial for Saroglitazar magnesium 2 mg in August 2017. The researchers wanted to see how safe, tolerable, and effective Saroglitazar Magnesium was in patients with primary biliary cholangitis (EPICS). The investigation is expected to be finished in March of 2019.
Request Here Sample with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-sample/2555
Manufacturers are working on therapeutic treatments for people with primary biliary cholangitis, which is likely to boost the market size for primary biliary cholangitis therapy. NGM Biopharmaceuticals, Inc., for example, announced positive findings from a phase 2 trial of NGM282 in patients with Primary Biliary Cirrhosis in March 2015. (PBC). NGM282 is a protein variation of the human hormone fibroblast growth factor 19 (FGF19) that keeps bile acid and metabolic regulating functions while removing FGF-19’s tumorigenic effects.
NGM282 is a powerful regulator of bile acid production, according to the findings of the study. Retrophin Inc. also purchased a liquid version of ursodeoxycholic acid from Asklepion Pharmaceuticals, LLC in June 2016. Ursodeoxycholic acid is a naturally occurring bile acid that dissolves cholesterol-rich gall bladder stones and enhances bile flow in primary biliary cholangitis. Furthermore, Intercept Pharmaceuticals, Inc. amended the prescribing instructions for Ocaliva (obeticholic acid or OCA) in the United States in February 2018 to stress proper dosing in patients with primary biliary cholangitis (PBC) who have Child-Pugh Class B or C or decompensated cirrhosis. However, a lack of knowledge among patients, families, and physicians, which leads to delayed diagnosis of rare diseases, could stymie the growth of the primary biliary cholangitis treatment market. The majority of symptoms linked with uncommon diseases are camouflaged by symptoms of common illnesses, and clinicians may be unable to diagnose them.
Get PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/2555
Key Takeaways:
Due to increased effort by key players to create prominent therapeutic options for the treatment of PBC, the global primary biliary cholangitis treatment market is estimated to grow at a CAGR of 36.3 percent during the projected period (2018– 2026).
The market is predicted to rise due to the rising prevalence of PBC in the United States. According to data from the National Center for Biotechnology Information (NCBI), the frequency of PBC in the United States grew from 21.7 to 39.2 per 100,000 people from 2006 to 2016.
Reasons to Purchase this Report
• Current and future of global Primary Biliary Cholangitis Treatment market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Table of Content
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Treatment Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Technology Advancements
- Pipeline Analysis
- Epidemiology
- Merger and Acquisition
- Regulatory Scenario
- Government Initiatives
- PEST Analysis
- Market Dynamics
- Global Primary Biliary Cholangitis Treatment Market, By Treatment Type, 2018 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Ursodeoxycholic acid (UDCA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Obeticholic acid (Ocaliva)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Introduction
- Global Primary Biliary Cholangitis Treatment Market, By Distribution Channel, 2018 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Introduction
- Global Primary Biliary Cholangitis Treatment Market, By Region, 2018 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, By Region, 2017 – 2026
- Regional Trends
- North America
- Market Size and Forecast, By Treatment Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Treatment Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Treatment Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Treatment Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Treatment Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Treatment Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bristol-Myers Squibb.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- NGM Biopharmaceuticals.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Lumena Pharmaceuticals, Inc,
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- TARGET PharmaSolutions,
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Intercept Pharmaceuticals, Inc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Retrophin, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Calliditas Therapeutics AB.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- GlaxoSmithKline (GSK) pharmaceuticals.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Novartis AG
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837